A detailed history of Russell Investments Group, Ltd. transactions in Inhibrx, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 190,389 shares of INBX stock, worth $2.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
190,389
Previous 435,450 56.28%
Holding current value
$2.7 Million
Previous $16.5 Million 59.78%
% of portfolio
0.01%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

SELL
$32.76 - $39.56 $8.03 Million - $9.69 Million
-245,061 Reduced 56.28%
190,389 $6.66 Million
Q4 2023

Feb 05, 2024

SELL
$14.5 - $38.0 $342,287 - $897,028
-23,606 Reduced 5.14%
435,450 $16.5 Million
Q3 2023

Nov 13, 2023

BUY
$15.75 - $26.31 $527,861 - $881,779
33,515 Added 7.88%
459,056 $8.42 Million
Q2 2023

Aug 10, 2023

BUY
$16.96 - $27.82 $1.82 Million - $2.98 Million
107,036 Added 33.61%
425,541 $11 Million
Q1 2023

May 09, 2023

SELL
$18.45 - $27.14 $19,188 - $28,225
-1,040 Reduced 0.33%
318,505 $6.01 Million
Q4 2022

Feb 08, 2023

SELL
$20.18 - $33.33 $424,970 - $701,896
-21,059 Reduced 6.18%
319,545 $7.87 Million
Q3 2022

Nov 04, 2022

BUY
$11.58 - $24.73 $1 Million - $2.14 Million
86,492 Added 34.04%
340,604 $6.11 Million
Q2 2022

Jul 29, 2022

BUY
$8.52 - $25.26 $761,151 - $2.26 Million
89,337 Added 54.22%
254,112 $2.88 Million
Q1 2022

May 05, 2022

SELL
$19.89 - $43.18 $1.87 Million - $4.05 Million
-93,806 Reduced 36.28%
164,775 $3.67 Million
Q4 2021

Jan 21, 2022

BUY
$26.75 - $46.02 $659,762 - $1.14 Million
24,664 Added 10.54%
258,581 $11.3 Million
Q3 2021

Nov 08, 2021

BUY
$25.18 - $37.81 $2.98 Million - $4.48 Million
118,467 Added 102.61%
233,917 $7.79 Million
Q2 2021

Aug 04, 2021

BUY
$14.69 - $27.52 $1.7 Million - $3.18 Million
115,450 New
115,450 $3.18 Million

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.